Aflibercept · intravitreal injection
Injections & Implants
Approved uses
Neovascular (wet) age-related macular degeneration
2 mg (0.05 mL of 40 mg/mL) intravitreally every 4 weeks for 3 months, then every 8 weeks
Every-4-week dosing gave no added efficacy over every-8-week in most patients after loading
Diabetic macular edema and diabetic retinopathy
2 mg (0.05 mL of 40 mg/mL) intravitreally every 4 weeks for the first 5 injections, then every 8 weeks
One regimen covers both; the label treats them together
Macular edema following retinal vein occlusion
2 mg (0.05 mL of 40 mg/mL) intravitreally every 4 weeks
Retinopathy of prematurity
0.4 mg (0.01 mL of 40 mg/mL) intravitreally; may be given bilaterally the same day and repeated in each eye, at least 10 days apart in the same eye
The only indication at a different strength, one fifth the adult dose
Contraindications
- Ocular or periocular infection
- Active intraocular inflammation
- Known hypersensitivity to aflibercept or any of the excipients in EYLEA (reactions may manifest as rash, pruritus, urticaria, severe anaphylactic/anaphylactoid reactions, or severe intraocular inflammation)
2 mg (0.05 mL of 40 mg/mL) single-dose pre-filled glass syringe, 2 mg (0.05 mL of 40 mg/mL) single-dose glass vial with injection components
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are members of the VEGF family of angiogenic factors that can act as mitogenic, chemotactic, and vascular permeability factors for endothelial cells. VEGF acts via two receptor tyrosine kinases, VEGFR-1 and VEGFR-2, present on the surface of endothelial cells. PlGF binds only to VEGFR-1, which is also present on the surface of leukocytes. Activation of these receptors by VEGF-A can result in neovascularization and vascular permeability. Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.
Warnings & Precautions
- Endophthalmitis, retinal detachment and retinal vasculitis: intravitreal injection has been associated with endophthalmitis and retinal detachment and, more rarely, retinal vasculitis with or without occlusion. Always use proper aseptic injection technique, and instruct patients and/or caregivers to report any signs or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay.
- Increased intraocular pressure: acute rises have been seen within 60 minutes of intravitreal injection, and sustained rises have been reported after repeated intravitreal dosing with VEGF inhibitors. Monitor and manage intraocular pressure and optic nerve head perfusion.
- Thromboembolic events: there is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including EYLEA. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). Reported rates were 1.8% with EYLEA versus 1.5% with ranibizumab in the first year of the wet AMD studies, and 3.3% with EYLEA versus 2.8% with control through week 52 of the DME studies.
- Reactivation of ROP: abnormal angiogenesis and tortuosity may reactivate after EYLEA. Monitor infants closely until retinal vascularization is complete or the examiner is sure ROP will not reactivate; treatment needs extended ROP monitoring, and more EYLEA injections or laser treatment may be necessary.
Common Side Effects
The most common adverse reactions (≥5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.
Pregnancy: Adequate and well-controlled studies with EYLEA have not been conducted in pregnant women. Aflibercept produced adverse embryofetal effects in rabbits, including external, visceral, and skeletal malformations. At the lowest dose shown to produce adverse embryofetal effects, systemic exposures were approximately 6 times higher than in humans after a single intravitreal treatment at the recommended clinical dose. Based on its anti-VEGF mechanism, EYLEA may pose a risk to human embryofetal development and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Females of reproductive potential are advised to use effective contraception prior to the initial dose, during treatment, and for at least 3 months after the last intravitreal injection.
Lactation: There is no information regarding the presence of aflibercept in human milk, the effects on the breastfed infant, or the effects on milk production/excretion. EYLEA is not recommended during breastfeeding.
The safety and effectiveness of EYLEA have been demonstrated in two clinical studies of pre-term infants with ROP. These two studies randomized pre-term infants between initial treatment with EYLEA or laser.